Roche's Avastin fails key colon cancer trial
April 22, 2009 at 03:08 AM EDT
Shares of Roche Holdings open 11% lower on Wednesday after the company says the key drug Avastin doesn’t reduce the risk of colon cancer returning any more than just using chemotherapy.
